Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.93 -0.14 (-0.52%)
Streaming Delayed Price Updated: 10:28 AM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
News headline image
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer, Merck And 3 Stocks To Watch Heading Into Tuesday ↗
U.S. stock futures up, Pfizer, Teradyne, Merck & Co., Palantir, and AMD expected to release earnings reports. Palantir and AMD beat estimates. 
Via Benzinga
News headline image
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those... 
Via MarketMinute
Topics Economy Government Intellectual Property
Pfizer Inc (NYSE:PFE) Emerges as a High-Quality Technical Breakout Candidate ↗
Via Chartmill
News headline image
Is Novo Nordisk Stock a Bargain Right Now? ↗
Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs. 
Via The Motley Fool
News headline image
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims ↗
UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from Pfizer about Beyfortus promotion. 
Via Benzinga
News headline image
Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗
Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following... 
Via Talk Markets
Topics Stocks
News headline image
Option Volatility And Earnings Report For February 2 - 6
Last week we saw a plethora of important earnings results and increased market volatility. This wee should be another busy one with a lot of important companies due to report. 
Via Barchart.com
News headline image
3 Headwinds Facing Pfizer in 2026 ↗
Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Earnings To Watch: Pfizer (PFE) Reports Q4 Results Tomorrow
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what investors should know. 
Via StockStory
News headline image
Here's Why Pfizer Stock Is Still a Buy ↗
Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting. 
Via The Motley Fool
Topics Intellectual Property
News headline image
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? ↗
Johnson & Johnson is a picture of stability. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗
All three can provide you with solid, consistent income. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property World Trade
News headline image
Should You Buy Guardant Health Before Feb. 19? ↗
This genomics stock appears to be at an inflection point. 
Via The Motley Fool
Topics Earnings
News headline image
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? ↗
The business may not be as strong as its performance this year suggests. 
Via The Motley Fool
News headline image
3 High-Yield Stocks to Buy Hand Over Fist in January ↗
If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close. 
Via The Motley Fool
Topics Economy
News headline image
This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years ↗
After a years-long revenue drought, there's a light at the end of the tunnel. 
Via The Motley Fool
News headline image
Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility
As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial... 
Via TokenRing AI
Topics Artificial Intelligence Economy
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
Looking for the most active stocks in the S&P500 index on Tuesday? ↗
Via Chartmill
News headline image
The Analyst Verdict: Pfizer In The Eyes Of 7 Experts ↗
 
Via Benzinga
News headline image
2 Biotech Stocks Set to Rebound in 2026 ↗
They could perhaps see sustained runs beyond this year. 
Via The Motley Fool
News headline image
Why Is Pfizer Stock Rising Tuesday? ↗
Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for the... 
Via Benzinga
News headline image
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer&#39;s Drug ↗
Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model. 
Via Benzinga
News headline image
Where Will Eli Lilly Be in 10 Years? ↗
Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
What Are Wall Street Analysts' Target Price for Pfizer Stock?
Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook. 
Via Barchart.com
Topics ETFs
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.